Neoleukin Therapeutics (NASDAQ:NLTX – Get Rating) was downgraded by analysts at Bank of America from a “buy” rating to an “underperform” rating in a note issued to investors on Monday, September 12th, The Fly reports.
Several other research analysts have also weighed in on NLTX. HC Wainwright lowered their price objective on shares of Neoleukin Therapeutics from $22.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, September 12th. Piper Sandler lowered their price target on Neoleukin Therapeutics from $25.00 to $6.00 in a research report on Friday, May 27th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Neoleukin Therapeutics in a research report on Wednesday, July 6th.
Neoleukin Therapeutics Price Performance
Shares of NASDAQ:NLTX traded down $0.00 during midday trading on Monday, hitting $0.95. The stock had a trading volume of 79,493 shares, compared to its average volume of 292,692. Neoleukin Therapeutics has a 12 month low of $0.80 and a 12 month high of $8.17. The business’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.28.
Institutional Trading of Neoleukin Therapeutics
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
- Get a free copy of the StockNews.com research report on Neoleukin Therapeutics (NLTX)
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger’s is Your One-Stop Consumer Staples Stock
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.